Cancer nanotechnology: current status and perspectives

Nano Convergence, Journal Year: 2021, Volume and Issue: 8(1)

Published: Nov. 2, 2021

Modern medicine has been waging a war on cancer for nearly century with no tangible end in sight. Cancer treatments have significantly progressed, but the need to increase specificity and decrease systemic toxicities remains. Early diagnosis holds key improving prognostic outlook patient quality of life, diagnostic tools are cusp technological revolution. Nanotechnology steadily expanded into reaches chemotherapy, radiotherapy, diagnostics, imaging, demonstrating capacity augment each advance care. Nanomaterials provide an abundance versatility, functionality, applications engineer specifically targeted medicine, accurate early-detection devices, robust imaging modalities, enhanced radiotherapy adjuvants. This review provides insights current clinical pre-clinical nanotechnological drug therapy, radiation therapy.

Language: Английский

---

A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer

Acta Pharmaceutica Sinica B, Journal Year: 2021, Volume and Issue: 12(1), P. 378 - 393

Published: June 18, 2021

The immune checkpoint blockade therapy has profoundly revolutionized the field of cancer immunotherapy. However, despite great promise for a variety cancers, efficacy inhibitors is still low in colorectal (CRC). This mainly due to immunosuppressive feature tumor microenvironment (TME). Emerging evidence reveals that certain chemotherapeutic drugs induce immunogenic cell death (ICD), demonstrating potential remodeling TME. In this study, ginsenoside Rg3 (Rg3) as an ICD inducer against CRC cells was confirmed using

Language: Английский

---

d -lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma

Science Advances, Journal Year: 2023, Volume and Issue: 9(29)

Published: July 19, 2023

The polarization of tumor-associated macrophages (TAMs) from M2 to M1 phenotype demonstrates great potential for remodeling the immunosuppressive tumor microenvironment (TME) hepatocellular carcinoma (HCC). d-lactate (DL; a gut microbiome metabolite) acts as an endogenous immunomodulatory agent that enhances Kupffer cells clearance pathogens. In this study, DL transformation TAMs was confirmed, and mechanisms underlying such were mainly due modulation phosphatidylinositol 3-kinase/protein kinase B pathway. A poly(lactide-co-glycolide) nanoparticle (NP) used load DL, DL-loaded NP modified with HCC membrane macrophage-binding peptide (M2pep), forming nanoformulation (DL@NP-M-M2pep). DL@NP-M-M2pep transformed remodeled TME in mice, promoting efficacy anti-CD47 antibody long-term animal survival. These findings reveal TAM modulatory function provide combinatorial strategy immunotherapy.

Language: Английский

---

Current advance of nanotechnology in diagnosis and treatment for malignant tumors

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Aug. 12, 2024

Cancer remains a significant risk to human health. Nanomedicine is new multidisciplinary field that garnering lot of interest and investigation. shows great potential for cancer diagnosis treatment. Specifically engineered nanoparticles can be employed as contrast agents in diagnostics enable high sensitivity high-resolution tumor detection by imaging examinations. Novel approaches labeling are also made possible the use nanoprobes nanobiosensors. The achievement targeted medication delivery therapy accomplished through rational design manufacture nanodrug carriers. Nanoparticles have capability effectively transport medications or gene fragments tissues via passive active targeting processes, thus enhancing treatment outcomes while minimizing harm healthy tissues. Simultaneously, context radiation sensitization photothermal enhance therapeutic efficacy malignant tumors. This review presents literature overview summary how nanotechnology used According oncological diseases originating from different systems body combining pathophysiological features cancers at sites, we most recent developments applications. Finally, briefly discuss prospects challenges cancer.

Language: Английский

---

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: April 21, 2023

As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, heat shock proteins. This leads to activation tumor-specific immune responses, which can act in combination with the direct killing functions drugs on cells further improve curative effects. In this review, we highlight mechanisms underlying ICD, those several chemotherapeutic DAMPs exposed during activate system, well discussing prospects application potential role immunotherapy, aim providing valuable inspiration future development chemoimmunotherapy.

Language: Английский

---

Nano Delivery of Chemotherapeutic ICD Inducers for Tumor Immunotherapy

Small Methods, Journal Year: 2023, Volume and Issue: 7(5)

Published: Jan. 5, 2023

Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is confirmed to activate the host immune system prevent, control, and eliminate tumors. Recently, a range chemotherapeutic drugs have been repurposed ICD inducers applied for tumor immunotherapy. However, several hurdles widespread application remain, namely poor water solubility, short blood circulation, non-specific tissue distribution, severe toxicity. Recent advances in nanotechnology pharmaceutical formulation foster development nano drug delivery systems tackle aforementioned expedite safe, effective, specific delivery. This review will describe barriers chemical highlight recent nanoformulations these

Language: Английский

---

Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(4), P. 413 - 424

Published: March 9, 2023

Language: Английский

---

Roles of reactive oxygen species in inflammation and cancer

MedComm, Journal Year: 2024, Volume and Issue: 5(4)

Published: April 1, 2024

Abstract Reactive oxygen species (ROS) constitute a spectrum of oxygenic metabolites crucial in modulating pathological organism functions. Disruptions ROS equilibrium span various diseases, and current insights suggest dual role for tumorigenesis the immune response within cancer. This review rigorously examines production its normal cells, elucidating subsequent regulatory network inflammation Comprehensive synthesis details documented impacts on diverse cells. Exploring intricate relationship between cancer immunity, we highlight influence existing immunotherapies, including checkpoint blockade, chimeric antigen receptors, vaccines. Additionally, underscore promising prospects utilizing targeting modulators as novel immunotherapeutic interventions discusses complex interplay ROS, inflammation, tumorigenesis, emphasizing multifaceted functions both physiological conditions. It also underscores potential implications immunotherapy suggests future research directions, development targeted therapies precision oncology approaches. In summary, this emphasizes significance understanding ROS‐mediated mechanisms advancing therapy developing personalized treatments.

Language: Английский

---

Immunological nanomaterials to combat cancer metastasis

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: 53(12), P. 6399 - 6444

Published: Jan. 1, 2024

This review highlights recent advances in immunological nanomaterials against metastasis and summarizes various nanomaterial-mediated immunotherapy strategies.

Language: Английский

---

Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies

Cell Death and Disease, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 7, 2025

Abstract Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with limited treatment options in advanced stages. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD1/PD-L1, has emerged as promising therapeutic approach. However, significant proportion patients exhibit primary or acquired resistance, limiting the overall efficacy immunotherapy. This review provides comprehensive analysis mechanisms underlying immunotherapy resistance GC, including role tumor microenvironment, dynamic PD-L1 expression, compensatory activation other checkpoints, and genomic instability. Furthermore, explores GC-specific factors such molecular subtypes, unique evasion mechanisms, impact Helicobacter pylori infection. We also discuss emerging strategies to overcome combination therapies, novel immunotherapeutic approaches, personalized based on genomics microenvironment. By highlighting these key areas, this aims inform future research directions clinical practice, ultimately improving outcomes for GC undergoing

Language: Английский

---